These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
126 related items for PubMed ID: 15470662
1. [The treatment of osteodystrophy in dialyzed uremic patients: results of the first Sardinian audit]. Mereu MC, Bolasco PG, Pinna A, Carzedda LG, Branca GF, Di Lauro L, Cogoni G, Solinas R, Mureddu S. G Ital Nefrol; 2004; 21(4):362-70. PubMed ID: 15470662 [Abstract] [Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V, Torregrosa V. Nefrologia; 2008 Nov; 28 Suppl 3():67-78. PubMed ID: 19018742 [Abstract] [Full Text] [Related]
7. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. Arenas MD, Alvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Nuñez C, Devesa R, Albiach B. J Nephrol; 2007 Nov; 20(4):453-61. PubMed ID: 17879212 [Abstract] [Full Text] [Related]
8. [Renal osteodystrophy in dialysis patients as estimated by three-point bone densitometry]. Kucharska E, Stompór T, Sułowicz W, Drozdz M, Kaczmarczyk I, Szymczakiewicz-Multanowska A, Chruściel B, Kraśnicka M. Przegl Lek; 2000 Nov; 57(6):334-9. PubMed ID: 11107868 [Abstract] [Full Text] [Related]
9. [Renal osteodystrophy Guidelines]. Messa P, Italian Society of Nephrology. G Ital Nefrol; 2003 Nov; 20 Suppl 24():S83-95. PubMed ID: 14666505 [Abstract] [Full Text] [Related]
10. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ogata H, Koiwa F, Shishido K, Kinugasa E. Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900 [Abstract] [Full Text] [Related]
12. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A. Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339 [Abstract] [Full Text] [Related]
13. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis. Mottet JJ, Horber FF, Casez JP, Descoeudres C, Jaeger P. J Bone Miner Res; 1996 Jan; 11(1):96-104. PubMed ID: 8770702 [Abstract] [Full Text] [Related]
14. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options]. Gallar P, Ortega O, Gutiérrez M, Muñoz M, Hilara L, Oliet A, Rodríguez I, Giménez E, Vigil A. Nefrologia; 2000 Jan; 20(4):355-61. PubMed ID: 11039261 [Abstract] [Full Text] [Related]